Inimmune, a Missoula-based biotech company founded by nationally recognized vaccine scientists that has been working on a vaccine for COVID-19, announced today that it has raised $22 million in Series A funding led by Two Bear Capital, a venture-capital firm founded by Whitefish philanthropist Mike Goguen.
The firm plans to use the Series A investment to advance at least two late-stage pre-clinical drug candidates in oncology and allergy through Phase I human clinical trials.